News
Osteopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2019 | PRLog
Osteopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2019. Osteopenia Therapeutics Market Forecast to Show Moderate Growth up to 2019 - PR11788332
Warner Chilcott CEO Discusses 2012 Guidance (Transcript) - Seeking Alpha
< p > Warner Chilcott plc ( < a href='http://seekingalpha.com/symbol/wcrx' title='Warner Chilcott Limited' > WCRX < /a > ) < /p > < p > 2012 Guidance Call < /p > < p > January 27, 2012 8:00 AM ET < /p > < p > < strong > Executives < /strong > < /p > < p > Paul Herendeen – EVP & amp; CFO < /p > < p
US Drug Watchdog Urges All Women Who Suffered An Out Of The Blue Broken Femur Or Thighbone To Call
The US Drug Watchdog is urging women, who suffered a broken femur, or thighbone fracture, for no apparent reason, while they were using the osteoporosis drug called Fosamax to call them, and get identified. According to the FDA, "Typically these fractures occurred after using any type of
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. By ...
Medical News: Osteoporosis Drugs Hike Femur Fracture Risk - in Endocrinology, Osteoporosis from
Use of bisphosphonates for osteoporosis increased the risk of femoral shaft fractures by nearly 50-fold in a large Swedish cohort study, but the absolute risk still remained very small, the investigat
Bisphosphonates, Approvals And Ongoing Studies At The EMA - Pharmaceutical Technology
The EMA has concluded a class review of bisphosphonates, adopted a number of positives opinions for new medicines and revealed more about the ongoing studies regarding GlaxoSmithKline's Pandemrix pandemic influenza vaccine and a possible link with narcolepsy.
Calls to boost bone therapy status - Yahoo! News UK
A drug that is at the back of the queue of osteoporosis treatments far outperforms the current "gold standard" therapy and boosts bone formation 17 times, a study has
Merck News Item
Merck & Co., Inc. home investors newsroom licensing careers contact us About Us Our Values Leadership How We Operate Views and Positions Merck/Schering-Plough Merger Our History Corporate Responsibility
Lancet: Paricalcitol + RAAS inhibitors VITAL for curbing renal risk
Adding a 2 ug/day dose of paricalcitol to a renin-angiotensin-aldosterone system (RAAS) inhibitor can safely reduce albuminuria in patients diagnosed with diabetic nephropathy, and could potentially reduce renal risk for diabetic patients, according to the VITAL trial published online Nov. 3 in the
Published Results Show Amgen's Denosumab Superior to Novartis Corporation's Zometa(R) in Delaying
<div class"xn-content"><p><span class"xn-location">THOUSAND OAKS, Calif.</span>,<span class"xn-chron">Nov. 8, 2010</span>/PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa
Refine by Content Type:
Refine by Source:
- www.thelancet.com (31)
- www.prweb.com (23)
- www.medpagetoday.com (14)
- www.merck.com (11)
- download.thelancet.com (9)
- www.australiandoctor.com.au (7)
- www.em-consulte.com (7)
- www.6minutes.com.au (6)
- www.prlog.org (6)
- www.webmd.com (5)
- www.biospace.com (5)
- www.medport.de (4)
